NCT02763800View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2001

Conditions
Parkinson's Disease
Interventions
DRUG

BIA 3-202

BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.

DRUG

Placebo

Matched placebo was administered in the form of oral tablets, given with 200 ml potable water

Trial Locations (1)

SE1 1YR

Guy's Drug Research Unit, London

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02763800 - Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202 | Biotech Hunter | Biotech Hunter